The Motley Fool Podcasts Industry Focus Healthcare: Why Amgen's Spending Billions To Buy This 1 Drug; Plus Heart Disease Has A New Enemy

Healthcare: Why Amgen's Spending Billions To Buy This 1 Drug; Plus Heart Disease Has A New Enemy Logo

Healthcare: Why Amgen's Spending Billions To Buy This 1 Drug; Plus Heart Disease Has A New Enemy

Amgen's $13.4 billion cash offer has won the bidding war for Celgene and Bristol-Myers Squibb's psoriasis drug, Otezla. Here's why the Goliath biopharma is betting so big on its success. Also, new data from The Medicines Company suggests a new cholesterol-busting drug is on it's way to approval. Stocks: CELG, BMY, AMGN, MDCO

Check out more of our content here:

Listen to Healthcare: Why Amgen's Spending Billions To Buy This 1 Drug; Plus Heart Disease Has A New Enemy

Recent Episodes

Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen
Listen

More Podcasts